Get informed when a big investor buys or sells
+ FollowNovember 4, 2026 - AI Summary
Overvalued by 94.2% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $133.37 Billion |
|---|---|
| Enterprise Value | $143.68 Billion |
| Annual dividend | $0.30 |
| Dividend yield | 1.96% |
| Earnings per Share | $0.14 |
| Beta | 0.83 |
| Outstanding Shares | 8,955,272,000 |
| P/E Ratio | 19.15 |
|---|---|
| PEG | 114.5 |
| Price to Sales | 7.34 |
| Price to Book Ratio | 7.34 |
| Enterprise Value to Revenue | 6.03 |
| Enterprise Value to EBIT | 59.08 |
| Enterprise Value to Net Income | 90 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.59 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured ...